Subclinical thyroid disorders

The Lancet

Volumn 380, Issue 9839, 2012, Pages 335-

  Goichot, Bernard ^a   Vinzio, Stéphane ^b  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b Groupe Hospitalier Mutualiste de Grenoble   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; COGNITION; GROUPS BY AGE; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SUBCLINICAL HYPOTHYROIDISM; SURVIVAL RATE; THYROID DISEASE;

EID: 84864212865     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61240-9     Document Type: Letter

References (5)

1. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012; 379: 1142-54.
2. Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC. Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br J Gen Pract 1993; 43: 107-09. (Pubitemid 23121696)
3. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526-34. (Pubitemid 30112276)
4. Turner MR, Camacho X, Fischer HD, et al. Levothyroxine dose and risk of fractures in older adults: a nested case-control study. BMJ 2011; 342: d2238.
5. The Lancet. Thyroid disease-more research needed. Lancet 2012; 379: 1076.